Evaluation of Time in Therapeutic Range of Patients with Non-Valvular Atrial Fibrillation on Oral Anticoagulation with Vitamin K Antagonist in Delta Region
Cardiology and Angiology: An International Journal,
Background: Non-valvular atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence as high as 1.5±2.0% in the general population. This arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. The aim of study was to evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range.
Patients and Methods: A total of 100 patients were included in this study for evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range.
Results: Our study showed that only 35% achieved the recommended TTR (percent time in therapeutic range) above 60% from studied risk factors, none showed statistical significance.
Conclusions: The quality of anticoagulant control was lower that reported in European countries with a significant proportion of patients had TTR below 60%.
- Non-Valvular atrial fibrillation
- oral anticoagulation
- Vitamin K antagonist
- delta region
How to Cite
Marinigh R, Lip GY, Fiotti N, Giansante C and Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J. Am. Coll. Cardiol. 2010;56(11):827-37.
Slot KB, Berge E, Dorman P, Lewis S, Dennis M and Sandercock P. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. 2008;336(7640):376-9.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-104.
Ogilvie IM, Newton N, Welner SA, Cowell W and Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med. 2010;123(7):638-45.e4.
Buckingham TA and Hatala R. Anticoagulants for atrial fibrillation: Why is the treatment rate so low?. Clin. Cardiol. 2002;25(10):447-54.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. J. Cardiothorac. Surg. 2016;50(5):e1-e88.
Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004; 126(6):1938-45.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012; 33(21):2719-47.
Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015; 131(2):157-64.
Apostolakis S, Sullivan RM, Olshansky B and Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013; 144(5):1555-63.
Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J. Am. Heart Assoc. 2013;2(1):e000067.
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-83.
Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakıllı Y, et al. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol. J. Cardiol. 2016; 16(8):595-600.
Farsad BF, Abbasinazari M, Dabagh A and Bakshandeh H. Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study. J. Clin. Diagn. Res. 2016;10(9):Fc04-fc6.
Zubaid M, Saad H, Ridha M, Mohanan Nair KK, Rashed W, Alhamdan R, et al. Quality of anticoagulation with warfarin across Kuwait. Hellenic J. Cardiol. 2013;54(2):102-6.
Maeder MT, König T, Bogdanovic S, Schneider I, Eugster W, Ammann P, et al. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. Swiss Med. Wkly. 2017;147:w14503.
Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res. Notes. 2014;7:891.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011;365(11):981-92.
Baker WL, Cios DA, Sander SD and Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 2009;15(3): 244-52.
Björck F, Renlund H, Lip GY, Wester P, Svensson PJ and Själander A. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiol. 2016;1(2):172-80.
Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am. J. Med. 2012; 125(8):773-8.
Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J. Thromb. Thrombolysis. 2013;35(3):333-5.
Melamed OC, Horowitz G, Elhayany A and Vinker S. Quality of anticoagulation control among patients with atrial fibrillation. Am. J. Manag. Care. 2011;17(3):232-7.
Abstract View: 217 times
PDF Download: 53 times